Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Polyvinyl alcohol (PVA) embolization microspheres combined with chemotherapy represent a standard interventional oncology treatment known as conventional transarterial chemoembolization (cTACE). The PVA microspheres are biocompatible, non-resorbable particles that act as a mechanical embolic agent, occluding the blood vessels that supply oxygen and nutrients to a tumor, thereby inducing ischemic necrosis. The chemotherapeutic component, which may include agents like doxorubicin, cisplatin, or mitomycin C, is typically emulsified with an oily contrast agent (like Lipiodol) and infused prior to or alongside the microspheres. This combination therapy is primarily utilized for the treatment of unresectable hepatocellular carcinoma (HCC) and certain liver metastases, aiming to achieve high local drug concentrations and prolonged tumor contact time while reducing systemic side effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polyvinyl alcohol embolization microspheres + chemotherapy.